We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Safety and efficacy of daratumumab in patients with multiple myeloma and severe renal failure.
- Authors
Kuzume, Ayumi; Tabata, Rikako; Terao, Toshiki; Tsushima, Takafumi; Miura, Daisuke; Narita, Kentaro; Takeuchi, Masami; Matsue, Kosei
- Abstract
IFLC levels just before the first daratumumab administration are as follows: Patient number (no.) 1, 68-4 mg/l; no. 2, 20-8 mg/dl; no. 3, 66-4 mg/l; no. 4, 447 mg/l; no. 5, 33900 mg/l; no. 6; 23-8 mg/l; no. 7, 598 mg/l; no. 8, 2435-3 mg/l; no. 9, 401 mg/l; no. 10, 283 mg/l; no. 11, 12 700 mg/l; no. 12, 664f0 mg/l. gl The most common adverse event (in four patients) was Grade 1/2 infusion reaction after the first dose. Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma patients. In general, adverse events of daratumumab in patients with severe RI are similar to those in patients without RI. There has been considerable improvement in the treatment of multiple myeloma (MM), but severe renal impairment (RI) owing to cast nephropathy (CN) is still one of the frequent complications requiring prompt treatment.
- Subjects
DARATUMUMAB; MULTIPLE myeloma; REGULATORY T cells; KIDNEY failure
- Publication
British Journal of Haematology, 2021, Vol 193, Issue 4, pe33
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.17412